Ernexa Therapeutics Inc. (NASDAQ:ERNA) Sees Significant Growth in Short Interest

Ernexa Therapeutics Inc. (NASDAQ:ERNA) was the recipient of a significant growth in short interest in August. As of August 14th, there was short interest totaling 24,656 shares, a growth of 68.8% from the July 30th total of 14,605 shares. Approximately 1.5% of the company’s stock are sold short. Based on an average daily volume of 47,948 shares, the days-to-cover ratio is presently 0.5 days.

Wall Street Analysts Forecast Growth

ERNA has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Ernexa Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Ernexa Therapeutics to a “hold” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Friday, July 17th. Finally, Brookline Capital Markets began coverage on shares of Ernexa Therapeutics in a research report on Thursday, May 7th. They issued a “buy” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ernexa Therapeutics has a consensus rating of “Hold” and an average target price of $30.00.

Ernexa Therapeutics Price Performance

NASDAQ:ERNA remained flat at $4.57 during mid-day trading on Monday. The company had a trading volume of 9,543 shares, compared to its average volume of 813,293. The firm has a market capitalization of $7.46 million, a PE ratio of -0.32 and a beta of 2.57. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $71.50. The company has a 50-day moving average of $5.13 and a 200 day moving average of $6.51.

Ernexa Therapeutics (NASDAQ:ERNA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($3.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.10). Sell-side analysts expect that Ernexa Therapeutics will post -18.02 EPS for the current fiscal year.

Institutional Trading of Ernexa Therapeutics

An institutional investor recently bought a new position in Ernexa Therapeutics stock. Susquehanna International Group LLP purchased a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.